Nutritive Effects of Cow's Milk-Based Formulas Through 18 Months of Age
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- University of North Carolina at Chapel Hill
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Singleton birth
- Gestational age of 37-42 weeks (36 weeks and six days is considered 36 weeks gestational age)
- Birth weight of 2500 g (5 lbs 8 oz) or more
- Parent(s) or legal guardian agrees not to enroll infant in another interventional clinical study while participating in this study
- Signed informed consent obtained for infant's participation in the study
- Signed authorization obtained to use and/or disclose Protected Health Information for infant from birth through 18 months of age
Infants receiving formula:
- 3 to 60 days of age at randomization, inclusive (day of birth is considered day 0)
- Exclusively receiving infant formula for at least 72 hours prior to randomization
- Parent(s) or legal guardian has full intention to exclusively feed study formula during the study period
Infants receiving human milk:
- 150-180 days of age at registration, inclusive (day of birth is considered day 0)
- Mother has intention to predominately provide mother's own breast milk through at least 10 months of age
Exclusion Criteria:
- Contraindication to magnetic resonance imaging (MRI)
- First degree relative with known autism, intellectual disability, schizophrenia, or bipolar disorder or an inherited disorder of myelination
- Major pre- and/or perinatal issues (such as maternal pre-eclampsia, placental abruption, maternal alcohol or illicit drug use during pregnancy)
- Major delivery complications (such as neonatal hypoxia or neonatal illness requiring a greater than 2-day NICU stay)
- Infant is immunocompromised (according to a doctor's diagnosis of immunodeficiency such as combined immunodeficiencies, DiGeorge syndrome, Wiskott-Aldrich syndrome, severe congenital neutropenia and secondary immunodeficiencies linked to HIV infection, Down syndrome or others)
- 5 minute APGAR < 7
- Infant was born large for gestational age (LGA) (as confirmed by the hospital birth records) from mother who was diabetic at childbirth
- Infant has been identified with inadequate weight gain or failure to thrive by a health care professional (HCP)
- History of underlying metabolic or chronic disease; congenital malformation; or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the infant to ingest food, the normal growth and development of the infant, or the evaluation of the infant
- Parent(s) or legal guardian unable to speak English at a level to provide informed consent
Infants receiving formula:
• Evidence of feeding difficulties or history of formula intolerance, such as vomiting or poor intake at time of randomization
Infants receiving human milk:
• Use of infant formula and/or donor milk more than three times per week prior to registration
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
アクティブコンパレータ:コントロール
|
Cow's milk-based formula
|
|
実験的:調査中
|
Cow's milk-based formula with added source of enriched whey protein
|
|
介入なし:Mother's-own Breast Milk
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
MR Imaging
時間枠:365 days of age
|
Brain Imaging
|
365 days of age
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
MR Imaging
時間枠:180 and 545 days of age
|
Brain Imaging
|
180 and 545 days of age
|
|
Gap Overlap Paradigm
時間枠:180 and 365 days of age
|
180 and 365 days of age
|
|
|
Visual Expectation Paradigm
時間枠:180 and 365 days of age
|
180 and 365 days of age
|
|
|
A-not-B Task
時間枠:365 and 545 days of age
|
365 and 545 days of age
|
|
|
Bayley Scales of Infant and Toddler Development, Third Edition
時間枠:365 and 545 days of age
|
365 and 545 days of age
|
|
|
Body Weight
時間枠:180, 365 and 545 days of age
|
180, 365 and 545 days of age
|
|
|
Length
時間枠:180, 365 and 545 days of age
|
180, 365 and 545 days of age
|
|
|
Head Circumference
時間枠:180, 365 and 545 days of age
|
180, 365 and 545 days of age
|
|
|
Recall of Study Feeding
時間枠:180, 275 (HM Reference group only), 365 and 545 days of age
|
Feeding Questionnaire
|
180, 275 (HM Reference group only), 365 and 545 days of age
|
|
Stool Microbiome Composition
時間枠:180, 365 and 545 days of age
|
Sequence analysis using QIIME 2.0 (quantitative insights into microbial ecology)
|
180, 365 and 545 days of age
|
|
Medically confirmed Adverse Events
時間枠:Through study completion, on average 18 months
|
Through study completion, on average 18 months
|
協力者と研究者
協力者
協力者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 6042
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。